期刊文献+

注射用头孢呋辛钠/他唑巴坦钠(4∶1)的急性和长期毒性研究 被引量:1

原文传递
导出
摘要 注射用头孢呋辛钠/他唑巴坦钠(4∶1)由第2代合成头孢菌素类抗生素头孢呋辛钠(Cefuroxime),与不可逆性竞争型β-内酰胺酶抑制剂按照4∶1组合而成的复方制剂。本项目的前期研究表明,头孢呋辛钠与他唑巴坦钠组成复方制剂,对大多数耐药且产β-内酰胺酶的细菌以及产ESBLs细菌均具有很好的协同抗菌作用,且无全身过敏性、局部刺激性和溶血性等制剂安全性方面的问题,抗菌效果明显强于单组分应用和对照抗生素,克服了头孢呋辛钠单独应用时的细菌耐药性问题[1-4]。
出处 《毒理学杂志》 CAS CSCD 北大核心 2013年第3期230-233,共4页 Journal of Toxicology
基金 海南省重点研究项目(090215)
  • 相关文献

参考文献6

  • 1邢桂兰,谢学立,曾渝,符健.注射用头孢呋辛钠他唑巴坦钠制剂安全性研究[J].海南大学学报(自然科学版),2011,29(2):143-146. 被引量:5
  • 2Fenoll A, Aguilar L, Robledo O, et al. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media[ J]. J Antimierob Chemother, 2007, 60 (2) : 323 -327.
  • 3Kalilman O, Giske CG, Samuelsen O, et al. Interplay of efflux, impermeability, and Ampc activity contributes to cefuroxime resistance in clinical, non-ESBL-producing isolates of Escherichia coli[ J]. Microb Drug Resist, 2009, 15(2) :91-95.
  • 4任晓华,崔文丽,张英,安翠平,霍卫池,杨慧芳,彭雯,冯涛,何士彦.我院大肠埃希菌耐药性分析[J].临床误诊误治,2012,25(3):84-85. 被引量:9
  • 5国家食品药品监督管理局.化学药物急性毒性试验技术指导原则[S].北京:中国医药科技出版社,2005.
  • 6国家食品药品监督管理局.化学药物长期毒性试验技术指导原则[S].北京:中国医药科技出版社,2005.

二级参考文献25

  • 1OZTOPRAK, NIHAL P, HANDE A R,et al. Piperacillin-taobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients : Results of an open randomized trial at a university hospital [J]. Nefise. Jpn J Clin Oncol,2010,40(8) :761 -767.
  • 2PAUL G, HILMAR W, DANUTA S, et al. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with-lactams against epidemiologically characterized multidmg-resistant Acinetobacter bau- mannii strains[ J ]. Antimicrobial Agents and Chemotherapy, 2004,48 (5):1586- 1592.
  • 3JALIL A, N1AZI ID, KHAN SU. Evaluation of restoration of sensitivities of resistant staphylococcus aureus isolates by using cefuroxime and clavulanic acid in combination[ J]. J Ayub Med Coll Abbottabad, 2008, 20(2) :28 -30.
  • 4国家食品药品监督管理局.化学药物刺激性、过敏性和溶血性研究技术指导原则[S].北京:罔家食品药品监督管理局,2005.
  • 5LILJA M, MAKITIE A A, ANTYILA V J, et al. Cefuroxime as a prophylactic preoperative antibiotic in septoplasty. A double blind randomized placebo controlled study [ J ]. Rhinology, 2011,49 ( 1 ) :58 - 63.
  • 6HUGO J, ISMAEL L, ANGI~LICA C, et al. Effect of severity disease on the pharmacokinetics of cefuroxime in children with multiple organ system failure[J]. Biol. Pharm. Bu11,2008,31(2) :316 -320.
  • 7BULITYA J B, LANDERSDORFER C B, KINZIG M, et al. New semiphysiological absorption model to assess the pharmaco- dynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics [ J ]. Antimicrobial Agents and Chemotherapy, 2009 ,53 ( 8 ) : 3462 - 3471.
  • 8KARADAG S, OZKAN B, KARABAS V L, et al. Effect of cefuroxime and moxifloxacin on Staphylococcus epidermidis adher- ence to intraocular lenses [ J ]. Can J Ophthalmol,2009 ,44 :663 -667.
  • 9SCHUMACHER H, SCHEIBEL J, MOLLER J K. Cross-resistance patterns among clinical isolates of Klebsiella pneumoniae with decreased susceptibility to cefuroxime [ J ]. J Antimicrob Chemother,2000,46 (2):215 -221.
  • 10FENOLL A, AGUILAR L, ROBLEDO O, et al. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media[J]. J Antimicrob Chemother, 2007,60(2) :323 - 327.

共引文献11

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部